Publications by authors named "Mark Shilkrut"

Claim this Profile
P
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera, Mark Shilkrut

Breast Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms.
James C Yao, Jonathan Strosberg, Nicola Fazio, Marianne E Pavel, Emily Bergsland, Mark Shilkrut

Endocr Relat Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to E. Hindié and K.R. Hess.
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mark Shilkrut

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma.
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mark Shilkrut

J Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases.
Mark Shilkrut, Eli Sapir, Sheela Hanasoge, Matthew J Schipper, Daniel P Normolle

Am J Clin Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
Qiufei Ma, Mark Shilkrut, Zhongyun Zhao, Minming Li, Nicolas Batty

BMC Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.
Howard L Kaufman, Robert H I Andtbacka, Frances A Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut

J Immunother Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Robert H I Andtbacka, Sanjiv S Agarwala, David W Ollila, Sigrun Hallmeyer, Mohammed Milhem, Mark Shilkrut

Head Neck· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Robert H I Andtbacka, Merrick Ross, Igor Puzanov, Mohammed Milhem, Frances Collichio, Mark Shilkrut

Ann Surg Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
Mark Shilkrut, Patrick W McLaughlin, Gregory S Merrick, Jeffrey M Vainshtein, Daniel A Hamstra

Am J Clin Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a novel platform-independent metastasis signature in human breast cancer.
Shuang G Zhao, Mark Shilkrut, Corey Speers, Meilan Liu, Kari Wilder-Romans

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
Qiufei Ma, Zhongyun Zhao, Beth L Barber, Mark Shilkrut

Adv Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.
Mark Shilkrut, Angela Wu, Dafydd G Thomas, Daniel A Hamstra

Mol Clin Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Mark Shilkrut, P William McLaughlin, Gregory S Merrick, Jeffrey M Vainshtein, Felix Y Feng

Int J Radiat Oncol Biol Phys· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
William C Jackson, Skyler B Johnson, Darren Li, Corey Foster, Benjamin Foster, Mark Shilkrut

Radiat Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Mark Shilkrut, Gregory S Merrick, P William McLaughlin, Matthew H Stenmark, Eyad Abu-Isa

Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
Michael A Augello, Craig J Burd, Ruth Birbe, Christopher McNair, Adam Ertel, Mark Shilkrut

J Clin Invest· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary malignancies in survivors of breast cancer: how to overcome the risk.
Mark Shilkrut, Yazid Belkacemi, Abraham Kuten,

Crit Rev Oncol Hematol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V.
Mark Shilkrut, Felix Feng, Daniel A Hamstra

Front Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Mark Shilkrut, Raquel Bar-Deroma, Gil Bar-Sela, Alison Berniger, Abraham Kuten

Am J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes.
Ofer Binah, Katya Dolnikov, Oshra Sadan, Mark Shilkrut, Naama Zeevi-Levin

J Electrocardiol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in the contraction.
Katya Dolnikov, Mark Shilkrut, Naama Zeevi-Levin, Sharon Gerecht-Nir, Michal Amit

Stem Cells· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes.
Yaron D Barac, Naama Zeevi-Levin, Gal Yaniv, Irina Reiter, Felix Milman, Mark Shilkrut

Cardiovasc Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrogen peroxide predisposes neonatal rat ventricular myocytes to Fas-mediated apoptosis.
Gal Yaniv, Mark Shilkrut, Sarit Larisch, Ofer Binah

Biochem Biophys Res Commun· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional properties of human embryonic stem cell-derived cardiomyocytes.
Katya Dolnikov, Mark Shilkrut, Naama Zeevi-Levin, Asaf Danon, Sharon Gerecht-Nir

Ann N Y Acad Sci· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis